ライフサイエンスコーパス: nanomedicine

1 reflects the translational potential of this nanomedicine.

2 2D germanene to the field of photonic cancer nanomedicine.

3 ding blocks, providing an infrastructure for nanomedicine.

4 delivery efficiency is an important goal of nanomedicine.

5 plex promises a major advancement in nuclear nanomedicine.

6 bined therapeutic functions for personalized nanomedicine.

7 to excel in a wide range of applications in nanomedicine.

8 manifold applications, from biophotonics to nanomedicine.

9 uates new cancer targets for tumor-targeting nanomedicine.

10 tribute to poor intratumoral distribution of nanomedicine.

11 of PtNPs and their potential applications in nanomedicine.

12 design of size and charge dual-transformable nanomedicine.

13 e egg to break the ill-conceived illusion of nanomedicine.

14 suggest a general strategy for personalized nanomedicine.

15 d approach for addressing a major barrier in nanomedicine.

16 cular target is essential for tumor-targeted nanomedicine.

17 ving therapeutic effectiveness of anticancer nanomedicine.

18 interplay among endocytosis, metabolism and nanomedicine.

19 e interactions and has broad applications in nanomedicine.

20 uggesting applications in bioengineering and nanomedicine.

21 lete the construction of the multifunctional nanomedicine.

22 and thus may enable practical application in nanomedicine.

23 e fields of catalysis, materials and biology/nanomedicine.

24 r contribute to this groundbreaking field of nanomedicine.

25 phology is the key parameter for efficacy of nanomedicine.

26 en successfully designed with liposome-based nanomedicine.

27 ons such as in energy storage, catalysis and nanomedicine.

28 immunotherapy, as materials of the future in nanomedicine.

29 o renal clearance-characteristics needed for nanomedicines.

30 for advancing clinical translation of cancer nanomedicines.

31 nd performance of intravenously administered nanomedicines.

32 "blackbox" by nanoresearchers in translating nanomedicines.

33 determine individual complement responses to nanomedicines.

34 ign of safe nanomaterials and more effective nanomedicines.

35 izons for the next generation of theranostic nanomedicines.

36 legant and efficient approach to combination nanomedicines.

37 consumer products, industrial materials, and nanomedicines.

38 role of imaging in the future development of nanomedicines.

39 urther improve the targeting efficiencies of nanomedicines.

40 ure opportunities for next-generation cancer nanomedicines.

41 otential dose-dependent in vivo transport of nanomedicines.

42 in adsorption and complement opsonization of nanomedicines.

43 ssed a three-stage development of UCNP-based nanomedicines.

44 onal approach for developing immune tolerant nanomedicines.

45 available, hampering the development of new nanomedicines.

46 ts and challenges for next-generation cancer nanomedicines.

47 ed STING agonists and other immunomodulating nanomedicines.

48 motes the circulation and tumor targeting of nanomedicines.

49 or assessment of NDDSs, that is, also future nanomedicines.

50 arkers can enhance specificity of anticancer nanomedicines.

51 e, the ETPN (European Technology Platform on Nanomedicine) [2], respectfully disagree.

52 Here, a polymeric siRNA nanomedicine (3I-NM@siRNA) stabilized by triple interact

53 CLM may be explored as a potential nanomedicine against breast cancer metastasis.

54 ar delivery also translated to a more potent nanomedicine against HER2-positive cells; incorporation

55 physiological stability compared to an siRNA nanomedicine analog that solely relies on the electrosta

56 With the convergence in materials science, nanomedicine and biology, multifunctional NIR-II phototh

57 We then review next-generation approaches in nanomedicine and drug delivery, focusing on preclinical

58 as been laid on ultrasmall nanoparticles for nanomedicine and eventual clinical translation.

59 ons in nanotechnology, biomaterials science, nanomedicine and healthcare, as additives for bulk const

60 exhibit durable response; the integration of nanomedicine and immunotherapy to address the above chal

61 al has been the most widely used material in nanomedicine and many other biomedical applications.

62 tein nanomaterials with properties useful in nanomedicine and material science applications.

63 ces of difficulty in clinical translation of nanomedicine and move forward ".

64 applications, including opto-bioelectronics, nanomedicine and mussel-inspired surface coating.

65 lly exaggerated, and the assumptions used in nanomedicine and nanoformulations turned out to be inapp

66 a interactions and that are relevant in both nanomedicine and nanotoxicology are discussed in a holis

67 implications in the fields of nanomaterial, nanomedicine and nanotoxicology, where assumption of the

68 ticles (NPs) is a paramount question in both nanomedicine and nanotoxicology.

69 ns in material chemistry, nanoscale physics, nanomedicine and structural biology.

70 or diagnostic platforms for next-generation nanomedicine and theranostics are discussed.

71 Overall, light-activated nanomedicines and DDSs are expected to provide more effe

72 TME) is a major cause of the failure of both nanomedicines and immunotherapies that not only limits d

73 ere is a bright future ahead for engineering nanomedicines and macroscale materials for immuno-oncolo

74 rts have been made in developing FR-targeted nanomedicines and nanoprobes and translating them into c

75 on the latest development of folate-mediated nanomedicines and nanoprobes for chemotherapy and diagno

76 al to simultaneously promote the delivery of nanomedicines and reduce immunosuppression in the TME.

77 lored, owing to the structural complexity of nanomedicines and the lack of relevant high-throughput s

78 of more efficient drug delivery nanosystems (nanomedicine) and to anticipate the fate and side-effect

79 ield has been overwhelmed by nanotechnology, nanomedicine, and many nano-sized drug delivery systems.

80 future directions in the area of phage-based nanomedicines, and discuss the state of phage-based clin

81 linical drug development paradigm for cancer nanomedicines, and the further development of chemo-immu

82 e become one of the most promising inorganic nanomedicines, and their biomedical applications have gr

83 ration of sophisticated delivery systems for nanomedicine applications generally involve multi-step p

84 of the most critical challenges for certain nanomedicine applications.

85 for their optimal use in nanotechnology and nanomedicine applications.

86 e severe side effects it can cause, numerous nanomedicine approaches have been developed to overcome

87 croenvironment could be modulated by various nanomedicine approaches to overcome hypoxia-associated r

88 ulus-responsive designs for improving cancer nanomedicine are discussed.

89 Nanomedicines are extensively employed in cancer therapy

90 tion of cancer nanomedicines, as most of the nanomedicines are sequestered by nontumor cells.

91 ring, with strong contributions to the whole nanomedicine area.

92 respect to applications in drug delivery and nanomedicine as a result of their biocompatibility and b

93 or implications in the translation of cancer nanomedicines, as most of the nanomedicines are sequeste

94 nic-translational applications of UCNP-based nanomedicines, as well as realization of our "one drug f

95 Thus engineered nanomedicine attain spherical entity with ~90 +/- 6 nm h

96 eted exosomal delivery systems for precision nanomedicine attract wide interest across areas of molec

97 ify new molecular targets for tumor-targeted nanomedicine based on a quantitative analysis.

98 Targeted inhibition of thrombin by a nanomedicine-based approach was protective without incre

99 arly efforts towards clinical translation of nanomedicine-based immunotherapy.

100 ative assessment of the tumor selectivity of nanomedicine-based systems.

101 seases and summarizes the latest advances in nanomedicine-based therapeutics and theranostics for tre

102 Then, we discuss the potential of a combined nanomedicine-based TME normalization and immunotherapeut

103 Here, we discuss how nanomedicine-based treatment strategies are well suited

104 are major biological barriers to translating nanomedicines because they sequester the majority of adm

105 xplorations will expand our understanding of nanomedicine behavior throughout all the physical and in

106 he importance of a thorough understanding of nanomedicines' biological performance, ranging from the

107 h as nucleic acids and genes are now used in nanomedicine, biosensors, microfluidics, and -omics to e

108 bit considerable promise for applications in nanomedicine, but until recently no convenient methods w

109 The nanomedicine can rapidly and effectively release its DOX

110 In the intracellular acidic environment, the nanomedicine can realize pH-triggered disassembly.

111 fined success for the clinically-used cancer nanomedicines can enable the design of next-generation n

112 Nanomedicines can modulate the behaviour of myeloid and

113 By contrast, nanomedicines can reduce - but do not eliminate - the ri

114 Contemporary approaches in nanomedicine center on the use of a single nanocarrier m

115 order to support the community, the European Nanomedicine Characterisation Laboratory (EUNCL) and the

116 sults can provide novel hints towards US and nanomedicine combined strategies for cell spectral imagi

117 Current cancer nanomedicines commonly suffer from poor tumor specificit

118 Here we report a pH/ROS dual-responsive nanomedicine consisting of beta-lapachone (Lap), a pH-re

119 plored to incorporate platinum warheads into nanomedicine constructs.

120 This nanomedicine could become a potent and safe therapeutic

121 identally, the same TME features that impair nanomedicine delivery can also cause immunosuppression.

122 tion, remineralization, tooth whitening, and nanomedicine delivery in clinical dentistry, as well as

123 the lessons learned regarding variations in nanomedicine delivery to different tumor types and betwe

124 clinical need, and the challenges hindering nanomedicines delivery should be conquered for strong th

125 Tailoring personalized cancer nanomedicines demands detailed understanding of the tumo

126 The developed 3I-NM@siRNA nanomedicine demonstrates effective at-site siRNA releas

127 The effectiveness of nanoparticles (NP) in nanomedicine depends on their ability to extravasate fro

128 promising for future clinical targeting NPs/nanomedicines design.

129 Only a tiny fraction of the nanomedicine-design space has been explored, owing to th

130 Combining favorable nanomedicine designs from individual studies may improve

131 nano-bio interactions, positively impacting nanomedicine development and their regulatory approval.

132 tegy of cross-technology innovation, support nanomedicine development as a high value and low-cost so

133 Nanomedicine development currently suffers from a lack o

134 nomedicines, how imaging studies are guiding nanomedicine development, and the role of imaging in the

135 Here we apply accelerated nanomedicine discovery to generate a potential aqueous p

136 Compared to free DOX, the biotin-modified nanomedicine displayed greatly increased cell uptake and

137 In mice having EAE, nanomedicines displaying either ubiquitous or CNS-specif

138 We have shown that pMHCII-based nanomedicines displaying liver autoimmune disease-releva

139 ty, and surface chemistry all play a role in nanomedicine drug delivery.

140 e-like proteins are of immense importance in nanomedicine due to their propensity to self-assemble fr

141 sult, this new DNA-GNR based multifunctional nanomedicine exerted greatly increased potency (~67 fold

142 h were largely ignored in traditional cancer nanomedicine experiments, should be carefully considered

143 e gap between cardiologists and regenerative nanomedicine experts.

144 Park argued that in the last 15 years nanomedicine failed to deliver the promised innovative c

145 New siRNA nanomedicines featuring triple-interaction stabilization

146 with mucosae by different mechanisms in the nanomedicine field have been extensively reported.

147 sify and Vyxeos), have demonstrated that the nanomedicine field is concretely able to design products

148 esign renders a greatly improved theranostic nanomedicine for efficient tumor suppression, and more i

149 urther expanding and growing the maturity of nanomedicine for global healthcare, accelerating the pac

150 show great promise in terms of personalized nanomedicine for patient-specific diagnosis and treatmen

151 e authors will summarize the applications of nanomedicine for RT cancer treatment, and pay particular

152 erapeutic promise as an effective and potent nanomedicine for the treatment of SHH MB.

153 a detailed investigation of shape effects in nanomedicine for this category of nanostructures.

154 evelop multifunctional and tissue responsive nanomedicines for a broad range of diseases.

155 The current nanomedicines for cancer therapy based on the enhance pe

156 CL nano-assemblies, compatibility, and novel nanomedicines for injection.

157 om the past successes and failures of cancer nanomedicines for its future applications in cancer immu

158 particles and opens a new pathway to develop nanomedicines for many diseases associated with glycocal

159 hybrid prodrug to construct self-deliverable nanomedicines for more effective combination chemotherap

160 ins and RNA, and are potential candidates as nanomedicines for the modulation of MDSCs.

161 In this context, multiple different nanomedicine formulations and macroscale materials have

162 Furthermore, the >400 nanomedicine formulations currently in clinical trials a

163 to support clinical translation of promising nanomedicine formulations should increase, not decrease.

164 They are currently exploited in several nanomedicine formulations.

165 pport the rapid translation of new liposomal nanomedicines from bench to bedside, new cost-effective

166 In cancer therapeutics, nanomedicine generally relies on the enhanced permeabili

167 Our objective was to study a radiation nanomedicine (gold nanoseeds) composed of 30-nm gold nan

168 Nanomedicine has been widely used for a wide range of bi

169 Combination therapy based on nanomedicine has gained momentum in oncology in recent y

170 opularity of biomimetic design principles in nanomedicine has led to therapeutic platforms with enhan

171 Clinical translation of cancer nanomedicine has significantly reduced the toxicity and

172 However, the field of nanomedicine has strong potential to address such challe

173 Proposed nanomedicine has three distinct compartments namely; pol

174 benefits to intracellular drug delivery from nanomedicine have been limited by biological barriers an

175 Recent advances in the field of nanomedicine have demonstrated that biomimicry can furth

176 of nanoscience and innovative techniques of nanomedicine have moved micro/nanoparticles (MNPs) to th

177 However, few nanomedicines have been successfully translated into cli

178 Dendrimer-based nanomedicines have shown great potential for clinical tr

179 erapeutic approaches (e.g., regenerative and nanomedicine) have shown promise to prevent HF postmyoca

180 y of alendronic acid with bone, the proposed nanomedicine hold promises in delivering drug to bone mi

181 gies targeting the TME using multifunctional nanomedicines hold great potential for anti-tumor therap

182 nd cancer, facilitating the expansion of the nanomedicine horizon.

183 describe recent advances in the labeling of nanomedicines, how imaging studies are guiding nanomedic

184 This increased attention to nanomedicine, however, has not fully translated into cli

185 The beginning of the end of the nanomedicine hype.

186 ane-coated laser-responsive shape changeable nanomedicine, I-P@NPs@M, is reported.

187 Here, three clinically relevant nanomedicines, i.e., high-density lipoprotein ([S]-HDL),

188 fined clinical success in the case of cancer nanomedicines: (i) physicochemical design principles, an

189 ding of the interactions driving the fate of nanomedicine in biological systems remains elusive.

190 One of the main goals of nanomedicine in cancer is the development of effective d

191 and support the development of personalized nanomedicine in the longer term.

192 vironment, can severely limit the utility of nanomedicine in the oncological setting.

193 icles is key to the future success of cancer nanomedicines in clinics.

194 We present an overview of cancer nanomedicines in four emerging oncology-associated field

195 e accumulation of intravenously administered nanomedicines in many pathological tissues.

196 ary covering recent progress in the field of nanomedicines in pyroptosis-based cancer therapy has not

197 The success of nanomedicines in the clinic depends on our comprehensive

198 Nanomedicines in the sub-100nm range have been suggested

199 h opens up a new path for precise control of nanomedicines in vivo.

200 Our results help elucidate nanomedicines' in vivo fate and provide guidelines for e

201 te bacteriophages (phages) can be applied in nanomedicine, in particular, as nanoprobes for precise d

202 Moreover, the application of nanomedicine including CRISPR nanoparticle, exosomes for

203 hage structures in many aspects of precision nanomedicine, including ultrasensitive biomarker detecti

204 forts are being made to modify the design of nanomedicines, including optimization of their physioche

205 ntered in the clinical translation of cancer nanomedicines inspire the community to more deeply under

206 nd stable compounds, and visualize how these nanomedicines interact with cognate T cells.

207 We discuss the incorporation of nanomedicine into these emerging disciplines, present pr

208 Nanomedicine introduces the possibility to administer dr

209 nsidered and incorporated into cancer immune nanomedicine investigations given their critical involve

210 Nanomedicine is extensively employed for cancer treatmen

211 iological processes that dictate the fate of nanomedicine is integral to developing more effective in

212 n of such size and charge dual-transformable nanomedicine is rarely reported.

213 osurgery strategies where a high uptake of a nanomedicine is required for effective and timely treatm

214 The rational design of nanomedicines is a challenging task given the complex ar

215 of GOx and l-Arg, a novel glucose-responsive nanomedicine (l-Arg-HMON-GOx) has been for the first tim

216 xisting radionuclides and radionuclide-based nanomedicines limits the efficacy of CR-induced theranos

217 With recent advances in the field of nanomedicine, many new strategies have emerged for diagn

218 Inspired by the emerging field of nanomedicine, many PET-based multimodality nanoparticle

219 The large volume and diversified nanomedicine market, undergoing a rapid growth, relies n

220 This potent, safe-to-use, and easy-to-apply nanomedicine may find broad use for eradicating toxic am

221 tors are potential candidates for preventing nanomedicine-mediated complement activation in human sub

222 Our results suggest that nanomedicine mimicking irinotecan and oxaliplatin as par

223 tudies indicate that our overall approach of nanomedicine needs serious reevaluation.

224 ades have witnessed the rapid development of nanomedicine (NM) which integrates the advancement of va

225 nd key considerations for rational design of nanomedicine of synergistic drug combinations for cancer

226 Nanomedicine of synergistic drug combinations has shown

227 cept in the field of drug delivery to obtain nanomedicines of high drug loading and high reproducibil

228 Nanomedicine offers unique advantages in treating human

229 delivering one-component new-chemical-entity nanomedicine (ONN) strategy to improve cancer therapy th

230 ion density) and identification of a ternary nanomedicine optimized to overcome important siRNA deliv

231 Radio-nanomedicine, or the use of radiolabeled nanoparticles i

232 This report represents a novel nanomedicine platform combining up-regulation of tumoral

233 Herein, an anti-adhesion nanomedicine platform is made by wrapping synthetic poly

234 ights into design principles for tailor-made nanomedicine platforms.

235 The development of nanomedicines presents the potential to deliver more pot

236 the market, and the recent approval of 3 key nanomedicine products (e.

237 These nanomedicines promote the differentiation of disease-pri

238 ery controllability and modular flexibility, nanomedicines provide opportunities to facilitate immuno

239 ze and charge; it offers effective and rapid nanomedicine purification with high lipid recovery (> 98

240 Successful bench-to-bedside translation of nanomedicine relies heavily on the development of nanoca

241 Nanomedicine represents an important class of cancer the

242 As such, proper design of cancer immune nanomedicine requires scrutiny of tumours' intrinsic and

243 ine - an approved malaria drug - is known in nanomedicine research for the investigation of nanoparti

244 xploited for targeted delivery of anticancer nanomedicines resulting in numerous pharmaceutical produ

245 Despite nanomedicine's remarkable potential and growth over the

246 This ETPN overview of achievements in nanomedicine serves to reinforce our drive towards furth

247 Ten pMHCII-based nanomedicines show similar biological effects, regardles

248 This nanomedicine shows prolong stability in serum and delive

249 ient intracellular delivery of an anticancer nanomedicine - specifically a HPMA copolymer-based drug

250 urthermore, we highlight the next generation nanomedicine strategies based on this novel chemistry.

251 gy, there have been great interests in using nanomedicine strategies to enhance radiation responses o

252 ions for designing preclinical cancer immune nanomedicine studies.

253 Promising advances in nanomedicine such as magnetic hyperthermia rely on a pre

254 pplications in which the MPhi is loaded with nanomedicines, such as liposomes ex vivo, so when the dr

255 Nanomedicines synergize with pharmacological and physica

256 eveloped as a high-efficiency antithrombotic nanomedicine targeted for collagen exposed on diseased b

257 eractions and developing immune-smart cancer nanomedicine that can take advantage of the body's immun

258 sponse against cancer is an emerging area of nanomedicine that has the potential to redefine the way

259 Nanomedicine that is able to target and deliver therapeu

260 Herein, a novel theranostic nanomedicine that targets both the chemical and biologic

261 is towards this perspective and focusing on nanomedicine that we take issue with Prof Park's recent

262 nes can enable the design of next-generation nanomedicines that can address some of the emerging chal

263 ns, and astrocytes) for different disorders, nanomedicines that can enable targeting of specific cell

264 ders and to highlight the recent advances in nanomedicines that can target specific disease-associate

265 Nanomedicines that co-deliver DNA, RNA, and peptide ther

266 the construction of responsive and activable nanomedicines that regulate the tumor microenvironment (

267 Nanomedicines - therapeutics composed of or formulated i

268 foster the development of successful cancer nanomedicine therapies.

269 This tumor-targeted, tocotrienol-based nanomedicine therefore significantly improved the therap

270 novesicles can represent a paradigm shift in nanomedicine: they may complement liposomes, showing the

271 , which may open up new avenues in designing nanomedicine through exploiting the tumor microenvironme

272 pMHCII-based nanomedicines thus represent a new class of drugs, poten

273 e, we summarized some strategies employed in nanomedicine to achieve specific cell targeting or to en

274 discuss the potential of these properties in nanomedicine to down-regulate inflammatory pathways or t

275 h imaging, and this requires labeling of the nanomedicine to enable detection outside the body.

276 have clinical utility as future personalized nanomedicine to manage neuroHIV/AIDS.

277 Nanomedicine to overcome both systemic and tumor tissue

278 cant route of administration for delivery of nanomedicine to the subarachnoid space.

279 value may be implemented in these NP-derived nanomedicines to achieve high levels of retention in tum

280 dvancement of nanotechnology, development of nanomedicines to efficiently target dysfunctional macrop

281 omising therapeutic agent of the metal-based nanomedicines to reduce cancer metastasis.

282 ry approvals are starting to be achieved for nanomedicines to treat a wide range of diseases.

283 stratification are urgently needed in cancer nanomedicine, to identify individuals suitable for inclu

284 propose four strategic directions to improve nanomedicine translation and exploitation.

285 r detoxification, a long-standing barrier in nanomedicine translation, can be turned into a bridge to

286 Peptide MHC class II-based (pMHCII-based) nanomedicines trigger the formation of multicellular reg

287 To optimally exploit nanomedicines, understanding their biological behavior i

288 w cytometry to evaluate the biodistribution, nanomedicines' uptake by plaque-associated macrophages/m

289 In-vitro bone targeting efficiency of nanomedicine was studied using hydroxyapatite crystals a

290 ouse osteosarcoma confirm the selectivity of nanomedicine when compared to its internalization in non

291 lastoma (GBM) by functionalizing 3I-NM@siRNA nanomedicine with angiopep-2 peptide is enhanced.

292 of this success, the interest in integrating nanomedicine with cancer immunotherapy to further improv

293 This design of nanomedicine with cascade reactions offers a promising s

294 n this review, we discuss the convergence of nanomedicine with immunotherapy with a focus on molecula

295 Development of liposomal nanomedicine with robust stability, high drug loading an

296 We engineered nanomedicine with the stealth corona made up of densely

297 Nuclear nanomedicine, with its targeting ability and heavily loa

298 it could play a central role in the field of nanomedicine, with novel perspectives for the developmen

299 ely has applications in material science and nanomedicine, with potential to evolve into related tech

300 f the endosomal transport mechanisms of many nanomedicines within cells.